Symposium on the eve of the European Development Days
Connecting the DOTS
Coughing up for TB
How to increase European contributions to speeding up the development of new tools?
Every day about 4,000 people die of TB. When the technology and science is almost there for dramatic improvements, why is this high potential endeavour not being supported? Globally there is a need for at least 1.45 billion Euros to be invested in research and development for new tools for TB, but only 290 million was allocated in 2007. This means there is a global deficit of 80%.
Read a summary of the symposium's discussions and key points.
Médecins Sans Frontières (MSF), the International Union Against Tuberculosis and Lung Disease, and Global Health Advocates/ACTION held a symposium.
Date: 21 October 2009
Place: Studio 3, Kulturhuset, Sergels torg, Stockholm
Speakers and participants explored the challenges of improving TB diagnostic tools and treatments in the context of severe public and private underfunding. Europe’s current support for research and development - and in particular weaknesses and gaps – were discussed, along with new mechanisms for stimulating research and product development.
Speakers and panelists included:
- Dr Christophe Fournier, President of MSF
- Dr Hans Rosling, Karolinska Institute and Gapminder.org
- Dr Pehrolov Pehrson, MSF Sweden, and Oliver Moldenhauer, MSF Germany
- Anna Hedin, Ministry of Health and Social Affairs, Sweden
- Dr Frauke Jochims, MSF Geneva
- Michelle Childs, MSF Access to Medicines Campaign
- Dr Nils Billo, International Union Against Tuberculosis and Lung Disease
- Dr Hannu Lang, European Commission
- Anders Ekholm, Ministry of Health and Social Affairs, Sweden
As a result of the March 2009 Paris meeting on defining test specifications for a TB Point-of-Care test, a briefing note was released entitled, "How to Boost the Development of a TB Point-of-Care Diagnostic Test".